Ouster Inc Ordinary Shares - Class A OUST 深 滬
已收盤 12-12 16:00:00 美东时间
24.26
-2.130
-8.07%
華盛通- 最 高26.075
- 今 開25.76
- 成交量 250.64万股
- 最 低 24.02
- 昨 收 26.39
- 總市值 14.56亿
- 52周最高 41.65
- 市盈率 靜 --
- 換手率 4.18%
- 52周最低 6.34
- 委 比 16.61%
- 總股本 6000.52万
- 歷史最高 261.50
- 量 比 1.67
- 振 幅 7.79%
- 歷史最低 3.752
- 每 手 1
- 風險率 9.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Shares of companies within the broader technology sector are trading lower amid weakness in Broadcom after it issued cautious outlook. The sector is also being weighed down by reports that Oracle delayed some data center projects for OpenAI.
Shares of companies within the broader technology sector are trading lower amid...
今天 04:20
美议员加戏：别用中国的了，万一打起来…
【文/观察者网 柳白】 把中国科技发展视作“钉子”的美政客，又抡起了“锤子”，这次被盯上的是激光雷达。 路透社12月11日报道称，美国众议院臭名昭著的反华机...
12-12 09:36
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Cantor Fitzgerald Upgrades Ouster to Overweight
Cantor Fitzgerald analyst Andres Sheppard upgrades Ouster (NASDAQ:OUST) from Neutral to Overweight.
11-07 05:28
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
WestPark Capital Reiterates Buy on Ouster, Maintains $50 Price Target
WestPark Capital analyst Casey Ryan reiterates Ouster (NASDAQ:OUST) with a Buy and maintains $50 price target.
11-06 00:25
Ouster Stock Surges On Better-Than-Expected Q3 Results
Ouster shares are rising in extended trading Tuesday after the company reports better-than-expected results for the third quarter.
11-05 06:45
Ouster shares are trading higher after the company reported better-than-expected Q3 financial results.
Ouster shares are trading higher after the company reported better-than-expecte...
11-05 05:57
Ouster Sees Q4 Sales $39.500M-$42.500M vs $40.500M Est
Ouster (NASDAQ:OUST) sees Q4 sales of $39.500 million-$42.500 million vs $40.500 million analyst estimate.
11-05 05:28
